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Abstract
The extracellular matrix (ECM) provides protection, rigidity, and structure toward 
cells. It consists, among others, of a wide variety of glycoproteins and proteoglycans, 
which act together to produce a complex and dynamic environment, most relevant 
in transmembrane events. In the brain, the ECM occupies a notable proportion of 
its volume and maintains the homeostasis of central nervous system (CNS). In ad-
dition, remodeling of the ECM, that is transient changes in ECM proteins regulated 
by matrix metalloproteinases (MMPs), is an important process that modulates cell 
behavior upon injury, thereby facilitating recovery. Failure of ECM remodeling plays 
an important role in the pathogenesis of multiple sclerosis (MS), a neurodegenerative 
demyelinating disease of the CNS with an inflammatory response against protective 
myelin sheaths that surround axons. Remyelination of denuded axons improves the 
neuropathological conditions of MS, but this regeneration process fails over time, 
leading to chronic disease progression. In this review, we uncover abnormal ECM 
remodeling in MS lesions by discussing ECM remodeling in experimental demyeli-
nation models, that is when remyelination is successful, and compare alterations in 
ECM components to the ECM composition and MMP expression in the parenchyma 
of demyelinated MS lesions, that is when remyelination fails. Inter- and intralesional 
differences in ECM remodeling in the distinct white matter MS lesions are discussed 
in terms of consequences for oligodendrocyte behavior and remyelination (failure). 
Hence, the review will aid to understand how abnormal ECM remodeling contributes 
to remyelination failure in MS lesions and assists in developing therapeutic strategies 
to promote remyelination.
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1  | INTRODUC TION
The extracellular space of all organs and tissues is composed of a 
network of molecules, essential for physical support of cellular com-
ponents and many cellular processes. This highly organized three-
dimensional molecular network is called the extracellular matrix 
(ECM). The ECM composition is specific for each organ or tissue, but 
the majority of components is comprised of proteoglycans, hyaluro-
nan, and fibrous (glyco)proteins, such as collagens, elastin, fibronec-
tin and laminin, and non-structural regulators, that is matricellular 
proteins such as tenascins, CCNs, SPARCs, fibulins, osteopontin, 
and thrombospondins (Theocharis, Skandalis, Gialeli, & Karamanos, 
2016). These components act together to produce a complex and 
dynamic environment, involved in cell surface and transmembrane 
events. Next to being a physical scaffold in which cells are embedded, 
ECM binds to adhesion receptors on cells, such as integrins, thereby 
regulating numerous cellular processes, including cell migration, dif-
ferentiation, proliferation, and survival (Rozario & DeSimone, 2010). 
Furthermore, the ECM functions as a reservoir for growth factors 
and other signaling molecules, thereby influencing cell behavior indi-
rectly. It may also act as a diffusion and migration barrier. Essentially 
all cell types synthesize and secrete ECM molecules. Variations in 
the composition and structure of ECM components affect both the 
overall structure and bioactive properties of the ECM, thereby af-
fecting signal transmission and thus the cellular response. The ECM 
is crucial for homeostasis, and is actively involved in repairing injury, 
whereas pathological conditions emerge from abnormalities in the 
ECM components.
In the central nervous system (CNS), the extracellular space takes 
up 17%–20% of the adult brain volume (Cragg, 1979; Nicholson & 
Sykova, 1998). Remarkably, while the ECM undergoes dynamic and 
continuous remodeling, mediated by matrix-degrading enzymes at 
normal and pathological conditions, ECM remodeling in the healthy 
adult CNS is very limited (Dityatev & Fellin, 2008; Rauch, 2007). 
As in all tissues, the ECM in the CNS can be classified in two major 
types that vary in structure, composition and regional appear-
ance: the pericellular matrices that are in close contact with cells 
and the interstitial matrices that surround cells. Examples of peri-
cellular matrices in the CNS include (a) the vascular and astroglial 
basement membranes that are present at the interface between 
endothelial cells and astrocytes, which play an important role in 
blood–brain barrier (BBB) maintenance (Lau, Cua, Keough, Haylock-
Jacobs, & Yong, 2013; Schreibelt et al., 2007; van Horssen, Dijkstra, 
& de Vries, 2007) and (b) neuronal-associated perineuronal nets that 
emerge during synaptogenesis, which preserve neuronal health by 
maintaining synaptic plasticity (Frischknecht & Seidenbecher, 2008; 
Kwok, Dick, Wang, & Fawcett, 2011; Oohashi, Edamatsu, Bekku, & 
Carulli, 2015). The dispersed ECM in the CNS parenchyma is a rep-
resentative example of an interstitial matrix. The interstitial ECM in 
healthy adult CNS contains relatively low levels of fibrous matrix 
proteins, like collagen, fibronectin, and laminin, which are mainly 
restricted to basement membranes (Ruoslahti, 1996; van Horssen 
et al., 2007). Instead, the adult interstitial ECM contains high levels of 
glycosaminoglycans (GAGs), either covalently attached to proteins, 
forming mainly chondroitin sulfate proteoglycans (CSPGs), particular 
lecticans, such as aggrecan, versican, and neurocan, or as unbound 
entities in the form of hyaluronan (Kwok et al., 2011; Rauch, 2007; 
Ruoslahti, 1996). Hyaluronan is the major component of healthy 
CNS, and is connected to CSPGs via linker proteins (Bignami, Hosley, 
& Dahl, 1993). Additional components of the adult ECM include the 
matricellular proteins of which tenascin-R and thrombospondin are 
most prominent in the CNS (Jones & Bouvier, 2014; Kwok et al., 
2011). Notably, the perineuronal nets are enriched in hyaluronan, 
tenascin-R, and CSPGs. All cell types of the CNS, that is astrocytes, 
microglia, oligodendrocytes, and neurons, as well as endothelial 
cells, contribute to the pool of proteins that eventually constitute 
the ECM (Lau et al., 2012).
The ECM of the CNS plays an important role in many regula-
tory processes during development and in the homeostasis of 
healthy adult CNS. In response to injury, the composition of the 
ECM changes, resulting in a transient ECM environment that may 
be either stimulatory or inhibitory to repair. Different neuropatho-
logical conditions are associated with a dysregulation of alterations 
in the expression pattern of ECM molecules, thereby impeding the 
K E Y W O R D S
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Significance
Demyelination and failure to remyelinate contribute to the 
neurological deficits that characterize the chronic progressive 
disease multiple sclerosis. Components of the extracellular 
matrix are involved in guiding each stage of the remyelination 
process, including oligodendrocyte progenitor cell migration, 
proliferation, and maturation. This review highlights the im-
portance of extracellular matrix remodeling in successful re-
myelination and links dysregulated matrix metalloproteinase 
expression in white matter multiple sclerosis lesions to ab-
normal inter- and intralesional expression patterns of ECM 
components and remyelination failure. Hence, this review 
will assist in developing therapeutic strategies to overcome 
remyelination failure and halt disease progression.
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process of repair, including regeneration. For example, a role of 
the dynamics and the distinct involvement of ECM components is 
becoming increasingly apparent in the demyelinating disease mul-
tiple sclerosis (MS), showing an association between ECM alter-
ations and white matter MS lesion formation (Satoh, Tabunoki, & 
Yamamura, 2009) and progression of the neuropathological state 
(Bonneh-Barkay & Wiley, 2009). ECM remodeling is tightly regu-
lated by an interplay between several proteins and enzymes of 
which the family of matrix metalloproteinase (MMP) is a prominent 
proteolytic system in the spatiotemporal regulation of the ECM 
(Lu, Takai, Weaver, & Werb, 2011; Page-McCaw, Ewald, & Werb, 
2007). Functional dysregulation of these enzymes contributes to 
the pathogenesis and progression of several inflammatory demy-
elinating diseases, including MS (Kieseier, Seifert, Giovannoni, & 
Hartung, 1999). Here, we aim to unravel abnormal ECM remodeling 
in MS lesions and link this to remyelination failure, as to assist in 
developing therapeutic strategies to promote remyelination in MS. 
To this end, we uncover abnormal ECM remodeling in MS lesions by 
describing and comparing the transient-altered expression patterns 
of individual ECM molecules and MMPs upon successful CNS re-
myelination in rodent models of toxin-induced demyelination, and 
upon remyelination failure in MS lesions. In addition, we discuss 
how the (transiently) expressed ECM proteins regulate the behav-
ior of cells that produce myelin, that is oligodendrocytes, and how 
their (persistent) expression may contribute to remyelination (fail-
ure). Also, the interactions between ECM molecules and MMPs and 
potential mechanisms leading to incorrect ECM remodeling in MS 
are reviewed. Before discussing this in more detail, we first present 
a brief overview of the pathology of MS.
2  | MULTIPLE SCLEROSIS
2.1 | Pathological hallmarks
MS is a neurodegenerative inflammatory disease of the CNS. It is 
one of the most common demyelinating CNS diseases with an in-
cidence of approximately 0.1% worldwide, while the prevalence 
varies based on geographical and ethnical differences (Compston & 
Coles, 2008; Rosati, 2001). Variable patterns of the clinical course 
of MS are observed. The most common form is relapsing-remitting 
MS, which is diagnosed in about 80% of the MS patients (Lublin & 
Reingold, 1996). Relapsing-remitting MS is characterized by relapses 
followed by full or partial recovery at the onset of the disease, but in-
complete recovery arises over time and the majority of patients de-
velop secondary progressive MS with minor remissions (Compston 
& Coles, 2008). Primary progressive MS is diagnosed in 10%–20% 
of the patients (Lublin & Reingold, 1996), has an onset at a later age, 
and is characterized by gradual accumulation of neurological defi-
cits, starting already at the onset of the disease (Compston & Coles, 
2008).
The disease is characterized by chronic and progressive loss of 
myelin sheaths surrounding the axons in the brain and spinal cord. 
The primary causative mechanism(s) resulting in demyelination and 
progression of MS is (are) still unclear. However, genetic predispo-
sition, that is mainly genes implied in (cell-mediated) immunity, and 
several environmental factors, such as vitamin D deficiency and viral 
infections, appear to play an important role in the development of 
MS (Compston & Coles, 2008; Correale & Gaitan, 2015; Olsson, 
Barcellos, & Alfredsson, 2017; Roch et al., 2017). These factors 
contribute to the inflammatory process occurring in MS, which is 
associated with disruption of the BBB. Whether this inflammation 
is a primary or secondary event in the pathogenesis of MS is un-
known (Compston & Coles, 2008; Stys, Zamponi, van Minnen, & 
Geurts, 2012). An autoimmune response  is initiated in the periph-
ery through (as yet unknown) processes. Molecular mimicry might 
underlie such an event, resulting in activation of autoreactive 
T cells against self-antigens, which migrate to the CNS. Subsequently, 
this might initiate an immune response, thus causing damage and 
degeneration. In contrast, cytodegenerative processes in the CNS 
through (as yet equally unknown) factors may activate autoreactive 
T cells by presentation of self-antigens and subsequently induce a 
secondary immune response. In MS, these autoreactive T cells are 
directed to self-antigens that include specific proteins, present on 
the surface of mature oligodendrocytes and/or in myelin (Mallucci, 
Peruzzotti-Jametti, Bernstock, & Pluchino, 2015). This results in 
(additional) demyelination due to the destruction of myelin and/or 
mature oligodendrocytes.
The formation of white matter MS lesions is a dynamic process 
resulting in interlesional heterogeneity. More specifically, distinct 
lesions are histopathologically classified in inflammatory and demy-
elinating activity (Kuhlmann et al., 2017; van der Valk & De Groot, 
2000). While different classification systems have been described, 
mainly three distinct lesions can be distinguished: active, mixed ac-
tive/inactive, and inactive lesions (Figure 1, (Kuhlmann et al., 2017)). 
Active lesions are the early demyelinating phenotype and are most 
frequently found in acute MS patients with a very short disease du-
ration (Frischer et al., 2015), while their proportion (approx. 25%) 
is similar upon longer disease duration and severity (Frischer et al., 
2015; Luchetti et al., 2018). Active lesions are defined by indistinct 
margins, harbor inflammatory activity, and contain a hypercellular 
lesion center with hypertrophic astrocytes, (myelin-laden) microg-
lia/macrophages, and lymphocytes. Mixed active/inactive lesions 
(also called “chronic active lesions” or “smoldering lesions”) show 
intralesional heterogeneity having a sharp border and consist of a 
hypocellular demyelinated lesion center with fibrous astrocytes. 
The lesion center is surrounded by a broad hypercellular inflam-
matory rim that contains microglia/macrophages and reactive as-
trocytes. The mixed active/inactive lesions are more frequently 
observed in progressive MS patients than in relapsing-remitting MS 
patients (Frischer et al., 2015; Luchetti et al., 2018). The final lesion 
classification is a (chronic) inactive MS lesion. These lesions have a 
hypocellular demyelinated center, containing mainly reactive astro-
cytes and show hardly signs of infiltration of microglia/macrophages 
or lymphocytes. Inactive lesions are also predominating in progres-
sive MS (Frischer et al., 2015).
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2.2 | Failure of remyelination
Myelin is an insulating layer around axons that provides axonal 
protection and electrical isolation, and mediates saltatory conduc-
tion of action potentials. The loss of activity due to demyelination 
is partially compensated by a redistribution of sodium channels 
along the demyelinated parts of the axon, which allows for non-
saltatory conduction with reduced velocity (Felts, Baker, & Smith, 
1997). However, this compensatory effect is only temporal and in 
conjunction with the loss of axonal protection, persistent demy-
elination leads to axonal damage and degeneration (Compston & 
Coles, 2008; Funfschilling et al., 2012; Lee et al., 2012). The rate 
of impulse transduction is reduced or the impulses cease, which 
results in clinical signs and symptoms of MS that reflect the af-
fected area of the CNS (Compston & Coles, 2008). In addition, 
accumulation of axonal degeneration is the main process that con-
tributes to progression of neurological dysfunction and disease 
severity (Compston & Coles, 2008; Papadopoulos, Pham-Dinh, & 
Reynolds, 2006). Progressive axonal loss is key to the continuous 
and irreversible neurological decline in progressive MS (Trapp & 
Nave, 2008). Next to primary axon damage, a major cause of ax-
onal loss in chronic stages of MS is secondary neurodegeneration 
as a consequence of remyelination failure (Irvine & Blakemore, 
2008). Indeed, in addition to ensure saltatory axonal conduction, 
myelinating oligodendrocytes secrete metabolic and trophic fac-
tors that maintain the integrity and survival of axons (Funfschilling 
et al., 2012; Lee et al., 2012). Therefore, prevention of axonal de-
generation might be beneficial to resolve the functional deficits 
and progression of MS.
A regenerative process to restore myelin is required to ensure 
the survival of demyelinated axons. This process is called remye-
lination, which re-establishes saltatory conduction, protects axons 
from degeneration and improves clinical features of MS (Franklin 
& ffrench-Constant, 2008; Franklin, Zhao, & Sim, 2002; Irvine & 
F I G U R E  1   Schematic overview of the inter- and intralesional heterogeneity of cells, extracellular matrix (ECM) proteins, and matrix 
metalloproteinases (MMPs) in active, mixed active/inactive and inactive white matter multiple sclerosis lesions. Lesions are indicted as 
pale (demyelinated) areas. ECM proteins and MMPs depicted in green have an increased expression and ECM proteins and MMPs depicted 
in red have a decreased expression compared to control white matter at the indicated location of the lesion, that is lesion center or rim. 
COL-V, collagen V; CSPGs, chondroitin sulfate proteoglycans; Fn, fibronectin; HA, hyalorunan; OPN, osteopontin; Tn-C, tenascin-C; 
Tn-R, tenascin-R; Vn, vitronectin. Thrombospondin-1 expression is increased in mixed active/inactive and inactive lesions, while data on 
localization are not available yet
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Blakemore, 2008; Jeffery & Blakemore, 1997; Smith, Blakemore, & 
McDonald, 1979). The myelin sheaths generated in the process of 
remyelination are shorter and thinner, compared to myelin sheaths 
produced during developmental myelination, but these newly- 
formed sheaths suffice for axonal protection and improved func-
tioning (Kornek et al., 2000). Experimental demyelination in ro-
dent models show that successful remyelination is not executed 
by pre-existing mature oligodendrocytes but achieved by newly- 
formed oligodendrocytes generated from local oligodendrocyte 
progenitor cells (OPCs; Zawadzka et al., 2010), while OPCs present 
in the adult subventricular zone contribute predominantly to remye-
lination of lesions in their proximity (Menn et al., 2006). In response 
to toxin-induced demyelination in these models, astrocytes and 
microglia are activated (reviewed by Franklin & ffrench-Constant, 
2008; Franklin et al., 2002). These changes lead to the (transcrip-
tional) activation of OPCs, resulting in morphological changes and 
enhanced gene expression of factors involved in oligodendrocyte 
differentiation and maturation (Arnett et al., 2004; Ferent, Zimmer, 
Durbec, Ruat, & Traiffort, 2013; Moyon et al., 2015; Reynolds et al., 
2002; Watanabe, Hadzic, & Nishiyama, 2004). In addition to OPC 
activation, microglia and astrocytes recruit and mediate the migra-
tion of OPCs to the demyelinated areas, where they further prolifer-
ate (Franklin & ffrench-Constant, 2008; Franklin et al., 2002; Levine 
& Reynolds, 1999). The final essential step is the generation of new 
myelin sheaths and involves the differentiation of OPCs into mature 
oligodendrocytes. The process includes contact between the oli-
godendrocyte and the axon, upregulation of myelin-specific genes 
and generation and compaction of the myelin membranes (Franklin 
& ffrench-Constant, 2008; Franklin et al., 2002). While in experi-
mental rodent models remyelination is executed by OPCs, carbon 
14-based birth dating and single nuclei RNA sequencing of MS brain 
tissue reveal that remyelination in MS is most likely not executed 
by OPCs, but by pre-existing mature oligodendrocytes (Jakel et al., 
2019; Schirmer et al., 2019; Yeung et al., 2019). Whether this is an 
inherent capacity of remyelination in humans, or an adaptation as 
of the inability of OPCs to differentiate to mature myelinating oli-
godendrocytes in MS lesions remains to be determined. However, 
in both cases, that is remyelination by newly-formed or pre-existing 
OLGs, new myelin membranes are formed.
A plethora of molecules play an important role in the different 
phases of remyelination, as well as several mediators of the inflam-
matory response, featuring in MS (Franklin & ffrench-Constant, 
2008; Franklin et al., 2002; Gaesser & Fyffe-Maricich, 2016; Hanafy 
& Sloane, 2011; Miron, 2017). Although remyelination is a natural 
response to demyelination in most cases, this regenerative process 
often fails in chronic and progressive MS (Compston & Coles, 2008; 
Franklin & ffrench-Constant, 2008; Goldschmidt, Antel, Konig, Bruck, 
& Kuhlmann, 2009; Kuhlmann et al., 2008; Lucchinetti et al., 1999; 
Luchetti et al., 2018). In a subset of lesions, insufficient migration 
and/or proliferation of OPCs likely accounts for remyelination fail-
ure. However, remyelination mainly fails due to defective OPC dif-
ferentiation (Franklin & ffrench-Constant, 2008; Franklin et al., 2002; 
Kuhlmann et al., 2008). In fact, in approx. 70% of both active and 
chronic MS lesions, OPCs are abundantly present (Chang, Tourtellotte, 
Rudick, & Trapp, 2002; Goldschmidt et al., 2009; Kuhlmann et al., 
2008; Lucchinetti et al., 1999; Strijbis, Kooi, van der Valk, & Geurts, 
2017; Wolswijk, 1998). Of interest in this respect is that single nuclei 
RNA sequencing of MS brain tissue shows that more dysregulated 
genes are found in mature oligodendrocytes rather than in OPCs com-
pared to tissue of healthy subjects (Schirmer et al., 2019). This may 
indicate that OPCs are indeed transcriptionally relatively quiescent in 
MS, likely as a reflection of the inhibitory environment in MS lesions 
for OPC differentiation. Remyelination not always fails in MS, given 
the presence of partly or completely remyelinated shadow plaques. 
Remyelinated shadow plaques are present at all stages of MS (Frischer 
et al., 2015; Goldschmidt et al., 2009; Kuhlmann et al., 2017; Luchetti 
et al., 2018) and is thus likely executed by pre-existing oligodendro-
cytes (Jakel et al., 2019; Yeung et al., 2019), but the frequency of re-
myelinated white matter shadow plaques is lower in the progressive 
forms compared to relapsing-remitting MS (Luchetti et al., 2018). This 
is likely a reflection of remyelination failure in mixed active/inactive le-
sions that are dominating at later stages. Notably, although extensive 
remyelination is occasionally observed at late-stage progressive MS 
(Patani, Balaratnam, Vora, & Reynolds, 2007; Patrikios et al., 2006), it 
is most prominently noted in acute lesions, that is immediately upon 
demyelination (Prineas et al., 1989; Raine & Wu, 1993).
Remyelination failure is thus thought to be a consequence of per-
turbations in the different phases of remyelination, that is activation, 
recruitment, and differentiation of OPCs, in which aging also plays 
an important role (Franklin & ffrench-Constant, 2008; Goldschmidt 
et al., 2009; Sim, Zhao, Penderis, & Franklin, 2002). The signaling 
and cellular environment, established by the state of the disease 
and lesion regulating these phases, is a crucial factor. Remyelination 
failure in MS is likely due to the presence of inhibitory signals or 
the lack of stimulatory signals in the damaged area. Indeed, various 
factors in the signaling environment of MS lesions are dysregulated, 
and together with ensuing cellular changes contribute to the fail-
ure of remyelination (Franklin & ffrench-Constant, 2008; Franklin 
et al., 2002; Hanafy & Sloane, 2011; Miron, 2017; Williams, Piaton, 
& Lubetzki, 2007). In this regard, a role of the dynamics and distinct 
interstitial ECM components in remyelination failure in MS lesions is 
becoming increasingly apparent (Lau et al., 2013; Satoh et al., 2009). 
In contrast, ECM remodeling benefits remyelination upon toxin- 
induced demyelination in rodent models, pointing to abnormal ECM 
remodeling in MS lesions, which is reviewed next.
3  | THE INTERSTITIAL ECM UPON 
DEMYELINATING INJURY
Dynamic remodeling of the ECM, that is transient expression and/
or degradation, is an effective mechanism to regulate glial cell be-
havior, including OPCs upon injury (reviewed in (Pu, Stephenson, & 
Yong, 2018)). Analysis of mRNA expression of ECM proteins and the 
MS lesion proteome reveals that mixed active/inactive and inactive 
MS lesions have a unique ECM composition, both when compared 
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among each other and to control white matter and active MS lesions 
(Hendrickx et al., 2017; Mohan et al., 2010; Satoh et al., 2009). This 
hints to interlesional heterogeneity of ECM proteins in MS lesions 
and that dysregulated ECM remodeling may play an important role 
in the pathogenesis of MS, including remyelination failure. To unravel 
abnormal ECM composition in the distinct MS lesions, experimental 
toxin-induced demyelination rodent models that show robust remy-
elination in the absence of the complex inflammatory background in 
MS are most instructive to obtain insight into the natural cellular and 
molecular responses during demyelination of the CNS and subsequent 
successful recovery. These toxin-induced demyelination models in-
clude the dietary cuprizone model (mice), which shows global demy-
elination most prominently in the corpus callosum (Praet, Guglielmetti, 
Berneman, Van der Linden, & Ponsaerts, 2014; Skripuletz, Gudi, 
Hackstette, & Stangel, 2011; Torkildsen, Brunborg, Myhr, & Bo, 2008), 
and the focal lysolecithin (mice and rat) and ethidium bromide (mice) 
models, where demyelination is induced by local injection of the toxin 
in the area of interest (Blakemore, 1976; Jeffery & Blakemore, 1995; 
Zhao, Li, & Franklin, 2006). Notably, in the lysolecithin model the BBB 
is disrupted (Muramatsu et al., 2015), while the endothelial cells re-
main seemingly intact in the cuprizone and ethidium bromide model 
(Bjelobaba, Begovic-Kupresanin, Pekovic, & Lavrnja, 2018; Kondo, 
Nakano, & Suzuki, 1987; McMahon, Suzuki, & Matsushima, 2002). In 
the following, we outline for each ECM protein transient changes in 
its expression in the interstitial matrix, that is parenchymal ECM, upon 
white matter demyelination and during remyelination in experimental 
rodent models, and indicate its presence in the distinct white matter 
MS lesions (summarized in Table 1 and Figure 1). In addition, we discuss 
direct effect(s) of each ECM protein on OPC behavior (summarized in 
Figure 2) and discuss how the protein may contribute to remyelination 
(failure). We only briefly touch upon changes in ECM composition of 
basement membranes, as remyelination-predetermined OPCs in gen-
eral do not face the ECM in basement membranes. For irregularities 
and alterations of ECM in basement membranes, we refer to two excel-
lent reviews by van Horssen et al. (2007) and Lau et al. (2013).
3.1 | Structural ECM proteins
CSPGs are the main proteoglycans of the CNS and consist of core 
proteins with covalently linked sulfated chrondroitin GAG side 
chains. The individual secreted CSPGs, that is neurocan, aggre-
can, versican, and phosphacan, differ in the composition of their 
core protein and/or the number and type of attached GAG chains. 
CSPGs can be produced by astrocytes, microglia/macrophages, 
neurons, and oligodendrocytes (Asher et al., 2002; Hibbits, Yoshino, 
Le, & Armstrong, 2012; Keough et al., 2016; Lau et al., 2012). 
CSPG expression, including versican and phosphacan, but not 
aggrecan, transiently increases upon lysolecithin- (Keough et al., 
2016; Lau et al., 2012) and/or cuprizone-induced demyelination 





InactiveDemyelination Remyelination Edge Center Edge Center
CSPGs ↑ = ↑ ↓ ↑ ↓ ↓
-Neurocan n.d. n.d. ↑ ↓ ↑ ↓ ↓
-Aggrecan = n.d. ↑ ↓ ↑ ↓ ↓
-Versican ↑ = ↑ ↓ ↑ ↓ ↓
-Phosphacan ↑ = = = = = =
Hyaluronan = = ↑ ↑ ↑
Collagen (V) = = ↑ = =
Fibronectin ↑ = ↑ ↑(aggregatesa) ↑(aggregatesa)
Vitronectin ↑ = ↑ ↑ = =
Laminin = ↑ = =  =
Tenascins       
Tenascin-C ↑ = ↓ ↓ = =
Tenascin-R ↑ = ↓ ↓ = =
Thrombospondin ↑ n.d. = ↑b  =b
Osteopontin ↑ = ↑ ↑  ↑
Note: Increased (↑), decreased (↓), and similar (=) expression of interstitial ECM proteins upon toxin-induced demyelination and in distinct white 
matter MS lesions compared to control.
Abbreviation: n.d., not determined.
aBased on biochemical analysis (Stoffels et al., 2013). 
bBased on MS lesion proteome (Satoh et al., 2009) and Western blot analysis (Sikkema et al., 2018), data on localization are not available yet. 
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(Hibbits et al., 2012). In lysolecithin-induced lesions, CSPGs are 
present in microglia/macrophages at the lesion center, while as-
trocytes harbor CSPGs at the lesion edges (Lau et al., 2012). 
Depositions of CSPGs, including aggrecan, neurocan and versican, 
are present in astrocyte-enriched edges of active and inactive MS 
lesions, while their expression is downregulated in the center of 
active, mixed active/inactive and in inactive lesions (Dahl, Perides, 
& Bignami, 1989; Hendrickx et al., 2017; Sobel & Ahmed, 2001). 
Gene expression profiling of rim and center of mixed active/ 
inactive and inactive MS lesions revealed that neurocan mRNA 
is enriched at the rim of mixed active/inactive lesions (Hendrickx 
et al., 2017). Deposited CSPG components in active MS lesions are 
suggested to be phagocytosed by foamy macrophages together 
with myelin debris (Sobel & Ahmed, 2001), although expression 
of CSPGs by macrophages cannot be excluded (Lau et al., 2012). 
Strikingly, phosphacan expression, which is a CNS-specific CSPG, 
is more or less preserved in active lesions, and, in general, less re-
duced in inactive MS lesions compared to the other CSPGs (Sobel 
& Ahmed, 2001). Also, in situ hybridization studies show the pres-
ence of phosphacan mRNA in remyelinating oligodendrocytes in 
MS lesions (Harroch et al., 2002), and suggested to be involved 
in oligodendrocyte lineage progression (Karus et al., 2016). Of 
interest, granular aggregates of versican and aggrecan, and to 
a lesser extent of neurocan, but not phosphacan are evident in 
normal appearing white matter (NAWM; Sobel & Ahmed, 2001). 
This indicates that ECM alterations in MS are not limited to the 
lesions themselves. In vitro studies revealed that CSPG coatings, 
including aggrecan, neurocan, and phosphacan, inhibit OPC ad-
hesion, process outgrowth and differentiation, likely by activat-
ing Rho-kinase-dependent signaling pathways via PTPσ (Keough 
et al., 2016; Lau et al., 2012; Lucchinetti et al., 1999; Pendleton 
et al., 2013; Siebert & Osterhout, 2011), as well as OPC migra-
tion in vivo (Siebert, Stelzner, & Osterhout, 2011). Exposure to 
soluble CSPGs impairs process outgrowth, but not differentiation 
(Lau et al., 2012; Pendleton et al., 2013). Moreover, soluble phos-
phacan is a ligand for oligodendroglial contactin and this complex 
inhibits OPC proliferation, and promotes OPC differentiation 
(Lamprianou, Chatzopoulou, Thomas, Bouyain, & Harroch, 2011). 
Thus, demyelination in experimental models leads to the upregula-
tion of CSPGs, which may have beneficial functions at early stages 
F I G U R E  2   Effect of extracellular matrix (ECM) proteins on oligodendrocyte progenitor cell (OPC) behavior relevant to remyelination. 
Successful remyelination upon central nervous system (CNS) demyelination in experimental rodent models involves the activation of 
adjacent OPCs, followed by recruitment (migration and proliferation) to and maturation (process arborization, differentiation, and myelin 
membrane formation) in the demyelinated area. The effect of structural ECM proteins, fibrous ECM glycoproteins, and matricellular proteins 
that are present in the interstitial ECM upon toxin-induced CNS white matter demyelination and/or distinct white matter MS lesions are 
shown. ECM proteins depicted in green increase and ECM proteins depicted in red decrease the indicated OPC behavior
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of recovery, that is to prevent premature OPC differentiation. 
Moreover, CSPGs are cleared to enable remyelination. Deposition 
of CSPGs in MS lesion edges may lead to the formation of a barrier 
for OPC migration into the lesions, and loss of CSPGs in the center 
may preclude their beneficial actions after recovery (Keough 
et al., 2016; Lau et al., 2012; Pu et al., 2018; Sobel & Ahmed, 2001).
Hyaluronan is a specialized non-sulfated GAG that functions as 
free, that is independent GAG molecule without protein core, or 
engages in non-covalent interactions with proteoglycans, including 
CSPGs (Sherman et al., 2002). Hyaluronan is expressed in different 
sizes, performing its functions in cell growth and motility and in-
teractions between different ECM molecules to stabilize the ECM 
(Bignami et al., 1993). Upon lysolecithin-induced demyelination, only 
a minimal accumulation of hyaluronan is noticed (Back et al., 2005), 
suggesting that there is no major upregulation of hyaluronan after 
demyelinating injury in this experimental rodent model. However, 
deposition of hyaluronan is associated with MS development 
(Nagy et al., 2019). In contrast to other glycosaminoglycans (Sobel 
& Ahmed, 2001), hyaluronan accumulates in the core of inflamma-
tory demyelinating active MS lesions (Back et al., 2005). In early le-
sions, infiltrating T cells and microglia probably produce hyaluronan 
and in chronic lesions, astrocytes are the likely source (Back et al., 
2005). Also, OPCs, and to a lesser extent mature oligodendrocytes, 
synthesize hyaluronan (Preston et al., 2013). Most interestingly, 
T cells and microglia produce low-molecular weight hyaluronan 
ranging from 200 to 400 kDa (LMW hyaluronan), whereas astro-
cytes produce hyaluronan with high-molecular weight, ranging from 
900 to 1,000 kDa (HMW hyaluronan; Back et al., 2005). Both HMW 
and LMW hyaluronan are present in MS lesions (Back et al., 2005; 
Preston et al., 2013). HMW hyaluronan is detrimental for remye-
lination when injected in lysolecithin-induced demyelinated lesions 
(Back et al., 2005). Treatment with soluble HMW hyaluronan or LMW 
hyaluronan inhibits OPC maturation through LMW hyaluronan- 
mediated activation of TLR2 (Back et al., 2005; Sloane et al., 2010). 
In fact, OPC maturation is only precluded when HMW hyaluronan is 
processed to a LMW form by a specific hyaluronidase (PH20) that is 
present in OPCs and astrocytes in lysolecithin-induced lesions and 
MS lesions (Back et al., 2005; Preston et al., 2013). Hence, digestion 
products of HMW hyaluronan as well as unprocessed LMW hyaluro-
nan likely prevent OPC maturation in chronic MS lesions, thereby 
contributing to remyelination failure (Figure 2; Preston et al., 2013).
Collagens are trimeric proteins containing long triple helical 
sequences that have the ability to form stable fibrils. They are ar-
ranged into networks and are involved in structuring and providing 
rigidity to the ECM. In the adult CNS, collagen is mainly limited to 
the basement membranes (e.g., collagen IV) and is hardly present in 
the interstitial matrix, which makes the brain a relatively soft tissue. 
While fibrillar collagens are not present in CNS parenchyma upon 
cuprizone-induced demyelination (Hibbits et al., 2012), fibrillar colla-
gen V is closely associated with astrocytes in the interstitial matrix of 
active MS lesions (Mohan et al., 2010). Furthermore, genes involved 
in collagen synthesis are highly expressed in the rim of inactive MS 
lesions (Hendrickx et al., 2017). Also, the accumulation of fibrillary 
collagens I and II is associated with perivascular inflammation in the 
center of active and mixed active/inactive MS lesions, and mainly 
restricted to basement membranes, playing a role in limiting the en-
largement of MS lesions (Mohan et al., 2010). MS proteome analy-
ses demonstrated an enrichment of collagen IV, primarily localizing 
in the basement membranes in inactive lesions (Satoh et al., 2009). 
Although OPCs lack collagen-recognizing integrins, OPC migration 
is inhibited on collagen I substrates (Milner, Edwards, Streuli, & 
ffrench-Constant, 1996), and collagen I microspheres support OPC 
differentiation (Yao, Phan, & Li, 2013). Therefore, the contribution of 
interstitial collagen to remyelination failure via direct modulation of 
OPC behavior in MS lesions is likely negligible.
3.2 | Fibrous ECM glycoproteins
Fibronectins are high-molecular weight glycoproteins that are pro-
duced by a single gene (Hynes & Yamada, 1982; Pankov & Yamada, 
2002). There are two types of fibronectin: plasma fibronectin and 
cellular fibronectin. Plasma fibronectin is a soluble compound 
that is generated by hepatocytes and circulates in the periphery 
(Owens & Cimino, 1982). Cellular fibronectin is insoluble and lo-
cally produced; in the CNS it is deposited by astrocytes, microglia/ 
macrophage, and endothelial cells (Hibbits et al., 2012; Stoffels et al., 
2013; Zhao, Fancy, Franklin, & ffrench-Constant, 2009). In normal 
healthy adult CNS, fibronectin is nearly absent in the interstitial 
ECM and only localizes to the vasculature (Sobel & Mitchell, 1989; 
Stoffels et al., 2013; van Horssen, Bo, Vos, Virtanen, & de Vries, 
2005; Zhao, Fancy, Franklin, & ffrench-Constant, 2009). Fibronectin 
is a major component of the transient ECM in various tissues upon 
injury guiding tissue repair, where it binds many other ECM com-
ponents to form matrices. In this manner, it regulates cell behavior 
via integrin receptors, in particular cell migration and proliferation 
(Pankov & Yamada, 2002; Singh, Carraher, & Schwarzbauer, 2010). 
Also, in various experimental toxin-induced lesions undergoing ef-
ficient remyelination, fibronectin is transiently expressed in white 
matter CNS parenchyma and upregulated in the vasculature and 
its level declines as remyelination proceeds (Espitia Pinzon et al., 
2017; Hibbits et al., 2012; Stoffels et al., 2013; Zhao et al., 2009). 
In active, mixed active/inactive and inactive white matter MS le-
sions, however, the increased vascular and extracellular fibronectin 
expression persists, and the protein is present in perivascular in-
filtrates (Sobel & Mitchell, 1989; Stoffels et al., 2013; van Horssen 
et al., 2005). In addition, fibronectin is associated with inflamma-
tion-mediated aggregation in chronic lesions (Stoffels et al., 2013). 
Fibronectin expression is still increased in remyelinated shadow 
plaques, but does not aggregate (Stoffels et al., 2013). Astrocytes 
are the predominant source of cellular fibronectin upon lysolecithin- 
induced demyelination (Stoffels, Hoekstra, Franklin, Baron, & 
Zhao, 2015), while in MS lesions fibronectin levels increase within 
demyelinated regions by both leakage from the blood circulation 
and production by reactive astrocytes (Sobel & Mitchell, 1989; 
Stoffels et al., 2013; van Horssen et al., 2005). Interestingly, white 
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matter astrocytes isolated from postmortem MS brain tissue show 
enhanced fibronectin aggregation compared to normal astrocytes 
that mainly deposit dimeric fibronectin (Stoffels et al., 2013). In 
vitro, dimeric fibronectin mediates OPC migration and proliferation 
(Baron, Shattil, & ffrench-Constant, 2002; Frost, Kiernan, Faissner, 
& ffrench-Constant, 1996; Milner et al., 1996; Stoffels et al., 2013; 
Tripathi, Parikh, Vora, Frost, & Pillai, 2017), while fibronectin coat-
ings prevent myelin membrane formation, likely by perturbing 
(secondary) process outgrowth, myelin-directed vesicle trans-
port, and formation of functional membrane microdomains (Baron 
et al., 2014; Buttery & ffrench-Constant, 1999; Lafrenaye & Fuss, 
2010; Maier et al., 2005; Siskova, Baron, de Vries, & Hoekstra, 
2006; Siskova et al., 2009; Stoffels et al., 2013). Similar to dimeric 
fibronectin, aggregates of fibronectin inhibit myelin membrane 
formation and myelination in mono- and co-culture systems (Qin 
et al., 2017; Stoffels et al., 2013). Thus, upon CNS white matter 
demyelination, transient expression of fibronectin precedes suc-
cessful remyelination, and may be beneficial in OPC recruitment, 
whereas the pathological fibronectin aggregates impair remyelina-
tion in MS lesions (Figure 2).
Vitronectin is another glycoprotein that is mainly localized 
in the vasculature of the adult CNS. The expression of microglia/ 
macrophages-derived vitronectin is transiently enhanced upon 
ethidium bromide-induced demyelination (Zhao et al., 2009). In MS, 
vitronectin is deposited in active lesions and at the edges of mixed 
active/inactive demyelinating lesions, where it is localized on the 
microvasculature, on demyelinated axons, and is present in a subset 
of hypertrophic astrocytes (Sobel, Chen, Maeda, & Hinojoza, 1995). 
Next to localized synthesis, part of the vitronectin acquires access 
into the brain, following passage across the disrupted BBB (Sobel 
et al., 1995). Vitronectin is absent in inactive lesions (Sobel et al., 
1995). It promotes migration and proliferation of cultured OPCs 
(Baron, Shattil, & ffrench-Constant, 2002; Frost, Kiernan, Faissner, 
& ffrench-Constant, 1996), indicating that vitronectin may regulate 
OPC recruitment, and that the absence of the compound in chronic 
lesions may contribute to the reduced number of OPCs in white mat-
ter MS lesions.
Laminins are self-polymerized and heterotrimeric glycoproteins 
that serve as major adhesive proteins in basement membranes. 
Multiple genes code laminin subunits, known as α, β, and γ polypep-
tide chains that assemble into distinct laminin variants (Colognato & 
Yurchenco, 2000). In the healthy adult CNS, laminins are predom-
inantly found at the vascular endothelial (mainly laminin-5, -8, and 
-10) and astroglial (mainly laminin-1 and -2) basement membranes 
(Sixt et al., 2001; van Horssen et al., 2005; Zhao et al., 2009). Upon 
CNS development, laminin-2 is localized to axons where it pro-
motes the maturation of OPCs into oligodendrocytes, OPC prolif-
eration, survival of oligodendrocytes, and myelination (Colognato 
et al., 2002; Colognato & Tzvetanova, 2011; Frost, Buttery, Milner, 
& ffrench-Constant, 1999; Leiton et al., 2015; Relucio, Tzvetanova, 
Ao, Lindquist, & Colognato, 2009; Relvas et al., 2001). Laminin-2 ex-
pression is upregulated upon CNS white matter demyelination and 
appears around axons at a time point that coincides with the onset 
of myelin membrane formation (Zhao et al., 2009), and may thus pro-
mote remyelination. In active and chronic MS lesions, the expression 
of laminin is mainly enhanced at the vascular and not in the lesion 
parenchyma (Esiri & Morris, 1991; Sobel, Hinojoza, Maeda, & Chen, 
1998; van Horssen et al., 2005), indicating that beneficial effects of 
laminin on oligodendrocyte behavior and remyelination may be ne-
gated in MS.
3.3 | Matricellular proteins
Matricellular proteins are non-structural regulators of the ECM 
that contain binding sites for other ECM proteins as well as cell 
surface receptors, and therefore play important roles in control-
ling cell behavior and ECM remodeling (Bornstein & Sage, 2002). 
Tenascin-C and tenascin-R are large hexameric and trimeric gly-
coproteins, respectively, assembled from monomers via disulfide 
bridges (Erickson & Inglesias, 1984; Norenberg, Hubert, & Rathjen, 
1996). The proteins are expressed in the normal adult CNS (Bartsch 
et al., 1992; Garcion, Faissner, & ffrench-Constant, 2001; Gutowski, 
Newcombe, & Cuzner, 1999) and bind to CSPGs, hyaluronan, and 
fibronectin (Chiquet-Ehrismann, 1991, 2004; Midwood, Chiquet, 
Tucker, & Orend, 2016). The expression of tenascin-R is specific to 
the CNS and produced by oligodendrocytes, as well by neurons dur-
ing development (Fuss, Wintergerst, Bartsch, & Schachner, 1993; 
Pesheva, Spiess, & Schachner, 1989), while tenascin-C is a more 
ubiquitous ECM protein (Midwood et al., 2016). In the CNS, tenas-
cin-C is expressed by astrocytes and oligodendrocytes (Bartsch 
et al., 1992; Czopka, Von Holst, Schmidt, ffrench-Constant, & 
Faissner, 2009; Garwood et al., 2004; Gotz, Bolz, Joester, & Faissner, 
1997; Gutowski et al., 1999; Prieto, Jones, Cunningham, Crossin, & 
Edelman, 1990). Upon ethidium bromide-induced demyelination, 
both tenascin-C and tenascin-R are upregulated and produced by 
reactive astrocytes and recruited OPCs, respectively (Zhao et al., 
2009). While tenascin-C and tenascin-R are enhanced at the gene 
expression level upon cuprizone-induced demyelination in one 
study (Zendedel et al., 2016), another study shows that tenascin-C 
mRNA is not strongly upregulated (Hibbits et al., 2012). In active 
MS lesions, both tenascin-C and tenascin-R are significantly down-
regulated, extending even beyond the edge of the lesion, that is 
at NAWM areas where the presence of macrophages is abundant 
(Gutowski et al., 1999). In the center of inactive MS lesions, the 
levels of tenascin-C and tenascin-R are almost similar to NAWM, 
while being reduced at the lesion rim (Gutowski et al., 1999). While 
tenascin-C mRNA levels are upregulated in inactive lesions com-
pared to NAWM (Zeis, Howell, Reynolds, & Schaeren-Wiemers, 
2018), tenascin-C and tenascin-R protein levels in active lesions re-
semble adjacent NAWM (Gutowski et al., 1999). Reactive astrocytes 
are likely the main producers of both tenascins in chronic lesions. 
Tenascin-R coatings function as a stimulator of OPC differentia-
tion and upregulate myelin proteins (Czopka, Von Holst, Schmidt, 
ffrench-Constant, & Faissner, 2009; Pesheva, Gloor, Schachner, & 
Probstmeier, 1997), while at least in vitro the formation of myelin 
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membranes is retarded (Czopka et al., 2009). Tenascin-C inhibits 
OPC migration (Frost et al., 1996; Garcion, Faissner, & ffrench-
Constant, 2001; Kiernan, Gotz, Faissner, & ffrench-Constant, 1996) 
as well as differentiation and myelin membrane formation (Czopka, 
von Holst, ffrench-Constant, & Faissner, 2010; Czopka et al., 2009; 
Garwood et al., 2004), while promoting OPC proliferation (Garcion 
et al., 2001) and survival (Garwood et al., 2004). Oligodendroglial 
contactin is involved in the tenascin-C-mediated inhibition of OPC 
differentiation (Czopka, von Holst, ffrench-Constant, & Faissner, 
2010). Thus, while its degradation in active MS lesions may initially 
benefit OPC migration, premature re-expression by reactive astro-
cytes in chronic lesions may maintain OPCs in an immature state.
Thrombospondin-1 is a trimeric matricellular protein that is pres-
ent in the adult CNS (Asch, Leung, Shapiro, & Nachman, 1986), ex-
pressed by astrocytes (Scott-Drew & ffrench-Constant, 1997) and 
involved in CNS synaptogenesis (Christopherson et al., 2005; Risher 
& Eroglu, 2012). Upon ethidium bromide-induced demyelination, 
thrombospondin-1 mRNA and protein are slightly upregulated at 
early demyelination (Zhao et al., 2009). Immunohistochemical anal-
ysis of thrombospondin in MS lesions has not been reported thus 
far. However, thrombospondin-1 mRNA levels are increased in ac-
tive and inactive MS lesions (Mohan et al., 2010), while thrombo-
spondin-1 protein levels are enriched in mixed active/inactive and 
inactive MS lesions (Satoh et al., 2009; Sikkema et al., 2018). Also, 
thrombospondin binds to fibronectin (aggregates) and collagen V 
(Adams & Lawler, 2011; Aho & Uitto, 1998; Sikkema et al., 2018), 
which are present in the interstitial ECM of MS lesions. In vitro, 
thrombospondin-1 coatings promote migration of an OPC-like cell 
line (Scott-Drew & ffrench-Constant, 1997), indicating that throm-
bospondin-1 may be involved in OPC recruitment.
Osteopontin is a secreted matricellular protein that binds di-
rectly to fibronectin and collagen (Giachelli & Steitz, 2000), and 
is expressed in grey but not in white matter in the normal adult 
CNS (Selvaraju et al., 2004; Shin, Cha, Chun, Chung, & Lee, 1999; 
Zhao, Fancy, ffrench-Constant, & Franklin, 2008). However, the 
protein is transiently upregulated in white matter upon cuprizone- 
(Selvaraju et al., 2004) and ethidium bromide-induced (Zhao, Fancy, 
ffrench-Constant, & Franklin, 2008) demyelination. Microglia/
macrophages and astrocytes show osteopontin immune reactiv-
ity (Selvaraju et al., 2004; Zhao et al., 2008), while only microglia/
macrophages harbor osteopontin mRNA (Zhao et al., 2008), and 
likely secrete osteopontin in the demyelinated areas. Microarray 
analyses showed that osteopontin mRNA levels are higher in active 
MS lesions than in control white matter (Chabas et al., 2001). In 
addition, proteomic analyses revealed that osteopontin protein is 
enriched in mixed active/inactive MS lesions compared to control 
white matter and inactive MS lesions (Satoh et al., 2009). Within 
active MS lesions, osteopontin is mainly present in macrophages 
and microvasucular endothelial cells, while reactive astrocytes 
also express osteopontin in active and mixed active/inactive MS 
lesions (Diaz-Sanchez, Williams, DeLuca, & Esiri, 2006; Sinclair, 
Mirakhur, Kirk, Farrell, & McQuaid, 2005). Moreover, osteopontin 
is also present in astrocytes in NAWM at areas with high levels of 
microglia activation (Chabas et al., 2001; Sinclair et al., 2005) and 
occasionally in white matter oligodendrocytes (Chabas et al., 2001; 
Diaz-Sanchez et al., 2006). Contrastingly, while protein levels are 
increased, gene expression analysis of adjacent NAWM, rim and 
center of mixed active/inactive and inactive lesions revealed a 
downregulation in osteopontin transcript levels (Koning, Bo, Hoek, 
& Huitinga, 2007). In vitro studies demonstrated that soluble osteo-
pontin induces proliferation in OPC-like cell lines and increases the 
expression of myelin basic protein (MBP) and myelin membrane for-
mation in mixed cortical cultures (Selvaraju et al., 2004). Although 
proliferation and differentiation are seemingly opposite processes, 
both are necessary for successful remyelination. Similar to an inte-
grin- and developmental stage-dependent switch in growth factor 
signaling (Baron, Colognato, & ffrench-Constant, 2005; Baron et al., 
2002; Colognato et al., 2002), the effect of osteopontin on OPC 
behavior may depend on the developmental stage and to which in-
tegrin it binds. Thus, osteopontin may mediate OPC proliferation 
via integrin αvβ3, whereas OPC differentiation may be induced by 
signaling via integrin αvβ5 (Blaschuk, Frost, & ffrench-Constant, 
2000). In favor of a developmental stage-dependent effect is that 
osteopontin is added to differentiating mixed cortical cultures 
(Selvaraju et al., 2004), that is when OPC proliferation is ceased. 
Alternatively, in mixed cultures the effect of osteopontin on OPC 
differentiation may be indirect. Hence, osteopontin may be benefi-
cial to remyelination at both OPC recruitment and OPC differenti-
ation levels (Figure 2).
The involvement of other matricellular proteins, including CCNs, 
SPARCs, and fibulins in ECM remodeling upon demyelination and in 
remyelination failure in MS, remains to be determined. Of interest 
is that Cyr61/CCN1 and CTGF/CCN2 associate with fibronectin ag-
gregates (Sikkema et al., 2018), and that CTGF/CCN2 inhibits OPC 
differentiation (Ercan et al., 2017; Lamond & Barnett, 2013), adding 
another level of complexity to fibronectin aggregate-mediated per-
turbation of OPC maturation. In addition, regulatory T cell-derived 
NOV/CCN3 promotes oligodendrocyte and myelination in demye-
linated toxin-induced lesions, although it is not clear whether CCN3 
acts directly on cells of the oligodendrocyte lineage or via other 
cells (de la Vega Gallardo, Dittmer, Dombrowski, & Fitzgerald, 2018; 
Dombrowski et al., 2017).
4  | DISTURBED ECM E XPRESSION IN MS 
LESIONS
When comparing the expression pattern of ECM molecules in the 
distinct MS lesions with the expression pattern of ECM molecules 
that are altered upon successful CNS remyelination in rodents both 
similarities and abnormalities are noticed (Table 1, Figure 1). In addi-
tion, inter- and intralesional heterogeneity in the localization of ECM 
proteins in the distinct white matter lesions is apparent. Why the 
expression of ECM proteins in MS lesions is abnormal, whether this 
affects remyelination, and what contributes to ECM heterogeneity 
in MS lesions are reviewed next.
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4.1 | Role of abnormal ECM in remyelination failure
Similar to demyelinating CNS white matter injury in experimental 
models, ECM molecules that are absent in the healthy adult CNS are 
upregulated upon demyelination in MS lesions, indicating a “normal” 
initial response to demyelination in MS lesions. These interstitial ECM 
proteins in general contribute to OPC migration and proliferation 
(Figure 2), and prevent premature OPC differentiation. In experimental 
models where remyelination is successful, the proteins are transiently 
expressed and cleared at the onset of remyelination to allow for OPC 
differentiation, among others by the increased expression of laminin 
(Zhao et al., 2008). In MS lesions, the initial transient increased ECM 
proteins persist, while the remyelination beneficial ECM protein laminin 
is virtually absent in the interstitial ECM MS. This indicates that the 
“normal” ECM remodeling response in MS lesions is derailed and not 
converted to a “remyelination-favoring mode” (Table 1 and Figure 1). 
Another striking difference is that CSPGs, present in the interstitial 
ECM CNS, are upregulated upon demyelination in experimental toxin-
induced demyelination rodent models, and downregulated at the center 
of white matter MS lesions. As CSPGs are present inside phagocytic 
macrophages in the center of active lesions (Sobel & Ahmed, 2001), 
CSPGs may be initially deposited in active MS lesions and cleared by 
macrophages.(Sobel & Ahmed, 2001). Whether the absence of CSPGs 
in inactive lesions is also the result of active clearance remains to be 
determined. CSPG proteins are merely inhibitory for OPC recruitment 
and differentiation (Figure 2), which in healthy CNS may keep the adult 
OPCs at their location in an immature state. Therefore, their transient 
degradation may be beneficial to remyelination. However, these ECM 
proteins are upregulated and not downregulated upon demyelination 
in experimental models, although their expressions at early time points, 
that is immediately upon induction of demyelination, have not been re-
ported thus far. Intriguingly, with regard to ECM expression, the edges 
of active and mixed active/inactive MS lesions resemble demyelinated 
areas in experimental models more than the core of MS lesions, with 
the exception of tenascins (Table 1 and Figure 1). Indeed, remyelination 
at the rim is more pronounced than that at the MS lesion center (Raine 
& Wu, 1993), suggesting that the interstitial ECM at the edges of active 
and mixed active/inactive lesions is more permissive for remyelination 
than the ECM in the center of the lesions. However, the degree of re-
myelination depends on the net ratio of myelination-supportive (e.g., 
laminin) and myelination-inhibitory ECM molecules (e.g., fibronectin 
aggregates, hyaluronan, CSPGs). In vitro, fibronectin-derived inhibitory 
signals dominate over myelination-promoting laminin signals (Baron 
et al., 2014), while only very high amounts of laminin can overcome 
the inhibitory effect of CSPGs on OPC differentiation (Lau et al., 2012; 
Sun et al., 2017) In fact, in some studies, the effect of CSPGs on OPC 
behavior have been performed on a relative high laminin background 
(Pendleton et al., 2013; Siebert & Osterhout, 2011), further indicating 
that CSPGs are likely dominant over laminin. Thus, given that aggre-
gates of fibronectin accumulate in chronic MS lesions and CSPGs at 
the edge of (chronic) active MS lesions, these remyelination-inhibiting 
obstacles have to be removed or their effects have to be bypassed to 
enable regeneration of myelin.
4.2 | Role of glial scar and inflammation
Astrocytes, microglia, and macrophages are the producers of ECM 
proteins in MS lesions. The astrocyte response in MS lesions is of 
dual nature, that is both astrocyte loss and astrogliosis are associated 
with remyelination failure (Correale & Farez, 2015; Nair, Frederick, 
& Miller, 2008; Williams et al., 2007). Major barriers that contrib-
ute to remyelination failure in MS are glial scars, that is astrogliosis, 
which parallels ECM alterations, and the ensuing inflammation. The 
changes in reactive astrogliosis are regulated in a context-specific 
manner (Sofroniew & Vinters, 2010), and given that the distinct 
cellular composition between the edge and center of, for exam-
ple, mixed active/inactive MS lesions, this may result in a different 
signaling environment and different extent of gliosis, and hence 
differences in ECM composition. Indeed, in MS lesions, antigenic 
differences that reflect the state of reactive astrocytes, that is be-
tween astrocytes at the lesion edge and center, exist (Holley, Gveric, 
Newcombe, Cuzner, & Gutowski, 2003; Park et al., 2019), indicating 
that at least two distinct glial scars are formed. The glial scar around 
the lesions is formed as a neuroprotective response to disruption of 
the BBB, and mainly prevents further expansion of the lesion (Nair 
et al., 2008). If so, it is tempting to suggest that the glial scar formed 
within the lesion center is a result of the fact that the required cells 
for tissue repair, that is cells that express the appropriate proteases 
that clear the transient ECM, could not reach the lesion site. Indeed, 
the edge of active and inactive MS lesions is mainly composed of 
CSPGs (Table 1 and Figure 1) that prevent the entry of inflammatory 
cells, including lymphocytes and macrophages in chronic MS lesions.
Thus, the different responses of astrocytes likely result in dif-
ferent reactive phenotypes that are present in the distinct MS 
lesions (John et al., 2002; Nair et al., 2008), which may account 
for the distinct interlesional and intralesional local ECM profile. 
Major contributors to the formation of glial scars are inflamma-
tory mediators, such as IL-1β, IL-10, TNFα, IFNγ, and TGFβ, as well 
as endogenous TLR ligands (Asher et al., 2000; John et al., 2004; 
John, Lee, & Brosnan, 2003; John, Lee, Song, Rivieccio, & Brosnan, 
2005; Sofroniew & Vinters, 2010). Importantly, the different levels 
and distinct composition of inflammatory cues are present in the 
distinct lesions and at the borders of expanding active MS lesions 
(Cannella & Raine, 1995; Koning et al., 2007; Woodroofe, Bellamy, 
Feldmann, Davison, & Cuzner, 1986). A glial scar barrier is absent 
in cuprizone-induced demyelination models, where inflammation 
does not play a major role (Hibbits et al., 2012), while removing the 
toxin leads to the clearance of ECM molecules and enables remy-
elination. In contrast, glial scars are formed in immune-mediated 
demyelination models such as experimental autoimmune enceph-
alomyelitis (EAE) and Theiler's murine encephalomyelitis (TME) 
that more closely resemble the situation in MS, including an in-
flammatory environment, and where remyelination is insufficient 
(Haist, Ulrich, Kalkuhl, Deschl, & Baumgartner, 2012; Smith & Eng, 
1987). For example, similar to MS lesions, in chronic relapsing 
EAE but not upon toxin-induced demyelination, astrocyte-derived 
HMW hyaluronan (Back et al., 2005) and fibronectin aggregates 
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(Stoffels et al., 2013) accumulate in lesioned areas. Also, CSPG 
proteins neurocan, aggrecan, brevican, and versican V1 are also 
increased at the peak of clinical EAE severity, whereas the expres-
sion of versican V2 is reduced (Sajad, Zargan, Chawla, Umar, & 
Khan, 2011; Stephenson et al., 2018). Aggrecan is only present in 
spinal cord grey matter, while versican V1 is also present in peri-
vascular cuffs and closely associated with infiltrating immune cells 
(Sobel & Ahmed, 2001). In TME, which is characterized by mild 
inflammation and insufficient OPC differentiation (Ulrich, Seeliger, 
Kreutzer, Germann, & Baumgartner, 2008), ECM alterations cor-
related with the development of astrogliosis and include among 
other intralesional deposition of laminin, tenascin-C, neurocan, 
and fibronectin, while phosphacan expression decreases and ag-
grecan expression remains similar (Haist et al., 2012).
Next to reactive astrocytes, other major cellular components that 
contribute to the dysregulated remodeling of the ECM in MS lesions 
are the resident microglia and the infiltrating macrophages. Microglia 
and macrophages are actively remodeling the ECM being producers 
of ECM proteins and of MMPs, that is proteases that are able to de-
grade and remodel the ECM (Lloyd & Miron, 2019). Given the complex 
beneficial and detrimental roles of microglia and macrophages in re-
myelination (Lloyd & Miron, 2019), and their mixed phenotype in MS 
lesions (Miron et al., 2013; Peferoen et al., 2015; Vogel et al., 2013), 
the persistent or incorrect expression of ECM molecules in MS lesions 
might result from altered expression patterns of microglia/macro-
phage-derived MMPs (Kieseier et al., 1999), which is discussed next.
5  | MMP s  UPON DEMYELINATING INJURY
MMPs are a family of proteolytic enzymes, also referred to as 
endopeptidases, that are essential for ECM remodeling in many 
processes. These include migration, wound healing, tissue morpho-
genesis, cell differentiation, neuronal growth, and several signaling 
processes (Lu et al., 2011; Page-McCaw et al., 2007). This family 
consists of 26 members, of which 24 are present in mammalian, 
divided into six subgroups: collagenases (MMP1, MMP8, MMP13), 
gelatinases (MMP2, MMP9), stromelysins (MMP3, MMP10, 
MMP11), matrilysins (MMP7, MMP26), membrane type (MT)-
MMPs (MMP14, MMP15, MMP16, MMP17, MMP24, MMP25), and 
other MMPs. All newly synthesized MMPs contain a signal peptide 
that is cleaved during transport via the secretory pathway. There 
are small differences in the structure of the MMPs, but three com-
mon domains are identified (Figure 3; Page-McCaw et al., 2007). 
F I G U R E  3   Schematic structure of the matrix metalloproteinase family. Matrix metalloproteinases (MMPs) share a conserved domain 
structure of a N-terminal pro-peptide and catalytic domain and a C-terminal hemopexin domain that is connected via a hinge region. MMPs 
are secreted or are membrane type (MT-MMPs) that are linked to the plasma membrane via transmembrane domain or by a GPI anchor
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A propeptide region is located at the N terminus of the protein, 
which prevents proteolytic activity through interaction with the 
catalytic domain. This domain is removed to activate the enzyme. 
The catalytic domain is also located at the N terminus, in which a 
zinc-binding motif is inserted. The catalytic domain of gelatinases 
contains an additional domain, called fibronectin type II-like do-
main. Except for matrilysins, the C-terminal part of MMPs contains 
a haemopexin-like domain, which is involved in substrate recog-
nition and anchoring, and interacts with the catalytic domain via 
a hinge region. The membrane type-MMPs (MT-MMPs) are mem-
brane proteins, whereas all other MMPs are secreted into the ex-
tracellular space. Here, they are able, however, to localize at the cell 
surface by binding to MT-MMPs and other cell surface molecules. 
MMPs have overlapping substrates, and in addition these enzymes 
are jointly capable of degrading virtually all ECM proteins. MMPs 
play also a crucial role in the shedding of growth factors, cytokines, 
chemokines, receptors, cell-adhesion molecules, and activation of 
other MMPs (Page-McCaw et al., 2007). Obviously, given this di-
versity, the activity of MMPs is tightly regulated. For expression, 
cells have to be activated for transcription of MMPs. The secreted 
forms require cleavage of the propeptide for activation, while MMP 
activity can be inhibited by tissue inhibitors of metalloproteinases 
(TIMPs; Lu et al., 2011; Page-McCaw et al., 2007).
In the healthy adult CNS, MMP activity is crucial in supporting 
cognitive processes, such as learning and memory, due to ECM re-
modeling and the regulation of synaptic plasticity and long-term 
potentiation (Agrawal, Lau, & Yong, 2008; Huntley, 2012). Also, the 
physiology of axons, myelin turnover, and angiogenesis are regulated 
by several MMPs. In addition, differential expression of MMPs in the 
development of the CNS is essential for neurogenesis and axonal 
growth as well as for the function of oligodendrocytes and myelin-
ogenesis. MMPs also play important roles in repair processes and in 
pathology, and both beneficial and detrimental functions have been 
assigned to MMPs in the injured CNS (Javaid, Abdallah, Ahmed, & 
Sheikh, 2013; Yong, 2005; Yong, Power, Forsyth, & Edwards, 2001). 
To remodel the ECM, demyelination and subsequent remyelination 
require a transient alteration in the expression pattern of MMPs. In 
addition, MMPs may affect OPC behavior by modulating the bio-
availability of several proteins, including growth factors and cyto-
kines (Dubois-Dalcq & Murray, 2000; McCawley & Matrisian, 2001). 
However, uncontrolled and abundant expression of MMPs may dam-
age the BBB, induce inflammation, and neurotoxicity, which may lead 
to (demyelinating) injury (Agrawal et al., 2008; Yong, 2005; Yong 
et al., 2001). Of interest, synergism among MMP2, MMP9, and MMP7 
genes may be a susceptibility factor for MS (Rahimi et al., 2016). In the 
following, we provide an overview of current insight into the role of 
distinct MMPs in successful remyelination and their expression in the 
distinct MS white matter lesions (summarized in Table 2 and Figure 1). 
Also, the consequence for demyelinating pathology is discussed.
5.1 | MMP3
Škuljec et al. (2011) investigated the expression profile of eleven 
MMPs (MMP2, MMP3, MMP7, MMP9, MMP10, MMP11, MMP12, 
MMP13, MMP14, MMP15, and MMP24) upon cuprizone-induced 
TA B L E  2   Expression of MMPs upon toxin-induced demyelination and in distinct white matter MS lesions and their MS relevant ECM 
targets
MMP MS relevant ECM targets
Experimental rodent models Multiple sclerosis
Demyelination Remyelination Active Mixed active/inactive Inactive
MMP2 Aggrecan, versican, neurocan, 
collagen V, fibronectin, laminin, 
vitronectin, tenascin-C (large)
= = ↑a ↑a =
MMP3 Aggrecan, versican, neurocan, 
phosphacan, collagen V, fibronectin, 
laminin, vitronectin, tenascin-C 
(large), osteopontin
↑ ↑ ↑ ↑b =
MMP7 Aggrecan, fibronectin, laminin, 
vitronectin, tenascin-C (large, small), 
osteopontin
= ↑ ↑a ↓b ↓b
MMP9 Aggrecan, collagen V, fibronectin, 
vitronectin, osteopontin
= ↑ ↑ ↑a =
MMP12 Aggrecan, fibronectin, laminin, 
vitronectin, osteopontin
↑ ↑ ↑ ↑a =
MMP19 Aggrecan, fibronectin, laminin, 
tenascin-C (large)
n.d. n.d. ↑ ↑a =
Note: Increased (↑), decreased (↓), and similar (=) expression compared to control.
Abbreviation: n.d., not determined.
aMarked expression at the edge. 
bAlso based on biochemical analysis (Wang et al., 2018). 
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demyelination and subsequent remyelination. At early demyelina-
tion, MMP3 mRNA is upregulated, followed by a return to normal 
levels during late stages of demyelination. A second more promi-
nent upregulation of MMP3 mRNA is observed upon remyelination, 
which is also reflected at the protein level (Skuljec et al., 2011; Wang 
et al., 2018). MMP3 mRNA levels, but not protein levels, are also 
increased upon early remyelination in the lysolecithin-induced de-
myelination model (Wang et al., 2018). At the protein level, MMP3, 
also referred to as stromelysin-1, is predominantly expressed by 
astrocytes, but may also be produced by damaged neurons, mi-
croglia, and oligodendrocytes following other types of CNS injury 
(Van Hove, Lemmens, Van de Velde, Verslegers, & Moons, 2012). An 
(early) upregulation of MMP3 is also observed in the inflammatory 
TME model (Hansmann et al., 2012; Ulrich et al., 2006), and in EAE 
(Weaver et al., 2005). In these inflammatory models with insufficient 
remyelination, MMP3 may aid to the disruption of the BBB. In ad-
dition, the early upregulation of MMP3 may cause the breakdown 
of myelin and exacerbate demyelination (Chandler, Cossins, Lury, 
& Wells, 1996; Shiryaev et al., 2009). In contrast, the upregulation 
of MMP3, observed at remyelination in the toxin-induced models, 
may facilitate myelin regeneration. MMP3 modulates several sign-
aling pathways, such as the bioavailability of some soluble growth 
factors, including IGF-1, that facilitate oligodendrocyte differentia-
tion and myelin production (D'Ercole, Ye, & O'Kusky, 2002; Dubois-
Dalcq & Murray, 2000; Fowlkes et al., 2004; McCawley & Matrisian, 
2001; Zeger et al., 2007). In addition, MMP3 degrades several ECM 
proteins, including CSPGs and fibronectin, and myelin debris, which 
are components that inhibit differentiation and maturation of oligo-
dendrocytes (Figure 2; Kotter, Li, Zhao, & Franklin, 2006; Lau et al., 
2012; Muir et al., 2002; Stoffels et al., 2013; Van Hove, Lemmens, 
Velde, Verslegers, & Moons, 2012). Hence, MMP3 may be benefi-
ciary of ECM remodeling to facilitate remyelination. MMP3 mRNA is 
not upregulated in MS lesions compared to white matter of healthy 
subjects (Lindberg et al., 2001). However, MMP3 protein is present 
in hypertrophic astrocytes in active and chronic white matter MS 
lesions, in microglia/macrophages in active lesions and on vascula-
ture in active and mixed active/inactive MS lesions (Maeda & Sobel, 
1996; Wang et al., 2018). Biochemical analysis revealed that MMP3 
protein levels were increased in mixed active/inactive MS lesions, 
but not inactive lesions compared to control white matter (Wang 
et al., 2018). Of interest, MMP3 is a potent activator of other MMPs, 
such as MMP7 and MMP9 (Lu et al., 2011; Maeda & Sobel, 1996; Van 
Hove et al., 2012), which are also prominently present in MS lesions 
(see below).
5.2 | MMP12
The expression level of MMP12, or macrophage elastase, is signifi-
cantly altered upon cuprizone-induced demyelination. At demyeli-
nation, MMP12 mRNA is predominantly produced by microglia/
macrophages (Skuljec et al., 2011). In this phase, MMP12 may func-
tion in cellular migration of macrophages through ECM remodeling 
and degeneration of myelin membranes through cleavage of MBP, 
one of the major myelin components (Chandler et al., 1996; Gronski 
et al., 1997; Shipley, Wesselschmidt, Kobayashi, Ley, & Shapiro, 
1996). The elevated expression pattern continued during remyelina-
tion, where MMP12 is produced by astrocytes and to some extent 
by oligodendrocytes, rather than microglia/macrophages (Skuljec 
et al., 2011). Upon remyelination, astrocyte-derived MMP12 may 
contribute to clearance of both myelin debris and the transient- 
expressed ECM proteins, and thus induce a stimulatory environment 
for remyelination. Also, during CNS development, MMP12 releases 
IGF-1 from IGF binding protein 6 and is required for process elon-
gation and OPC differentiation (Larsen, DaSilva, Conant, & Yong, 
2006; Larsen & Yong, 2004). Studies in EAE and TME models dem-
onstrated an upregulation of MMP12 by microglia/macrophages 
and a suggested role in disease progression and chronic phases 
of demyelination, respectively (Dasilva & Yong, 2008; Hansmann 
et al., 2012; Ulrich et al., 2006). In contrast, the EAE disease course 
is worse in MMP12 knockout than in wild type mice, which is medi-
ated in part by modulating the Th1/Th2 effector cytokine balance 
(Weaver et al., 2005) and MMP12-mediated cleavage of osteopon-
tin (Goncalves DaSilva, Liaw, & Yong, 2010). In fact, osteopontin 
is linked to relapses by enhancing the survival of activated T cells 
(Hur et al., 2007). This indicates that MMP12 is a protective mol-
ecule in EAE. In TME, MMP12 is likely involved in demyelination 
and extravasation of macrophages, and not in BBB damage or ECM 
remodeling (Hansmann et al., 2012). In MS lesions, MMP12 protein 
is present in foamy macrophages and upregulated within active 
demyelinating lesions, and at the rim of inactive MS lesions and to 
a lesser extent in the center of mixed active/inactive and inactive 
lesions (Vos, van Haastert, de Groot, van der Valk, & de Vries, 2003). In 
contrast to cuprizone-induced demyelination, in MS lesions, MMP12 
is not observed in astrocytes and oligodendrocytes. Hence, the pre-
dominant macrophage expression of MMP12 in active demyelinating 
MS lesions may have a dual role with regard to demyelination, that is 
it may induce death of activated T cells by cleaving osteopontin, but 
may also induce bystander demyelination by cleaving MBP. Notably, 
MMP12 is present at lower levels in cerebrospinal fluid (CSF) of MS 
patients compared to control CSF (Castellazzi et al., 2018).
5.3 | MMP9
MMP9, also called gelatinase B, is one of the most studied MMPs in 
MS. While MMP9 mRNA expression is unaltered upon cuprizone- 
induced demyelination compared to unlesioned white matter tis-
sue (Skuljec et al., 2011), MMP9 protein levels are upregulated 
predominantly in microglia and macrophages at the onset of remy-
elination upon lysolecithin-induced demyelination (Larsen, Wells, 
Stallcup, Opdenakker, & Yong, 2003). MMP9 mRNA and protein 
are upregulated in active and mixed active/inactive demyelinating 
MS lesions (Anthony et al., 1997; Cossins et al., 1997; Cuzner et al., 
1996; Lindberg et al., 2001; Maeda & Sobel, 1996; Mohan et al., 
2010). MMP9 mRNA expression is also upregulated in an EAE model 
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(Clements et al., 1997; Kieseier et al., 1998; Weaver et al., 2005), but 
not in the TME model (Ulrich et al., 2006, 2008). It is hypothesized 
that MMP9 is important for the infiltration of inflammatory cells into 
the CNS. Thus, the level of MMP9 is significantly increased in CSF 
and serum of MS patients with active disease, compared to healthy 
individuals (Bar-Or et al., 2003; Benesova et al., 2009; Fainardi et al., 
2006; Waubant et al., 1999). Injection of recombinant MMP9 into 
the CNS parenchyma resulted in breakdown of the BBB, neuronal 
and myelin loss (Anthony et al., 1998). The localization of MMP9 in 
cells present in perivascular areas, such as endothelial cells and the 
infiltrating cell population, including lymphocytes and macrophages, 
is also in favor of its contribution to the disruption of the BBB in MS 
(Cossins et al., 1997; Lindberg et al., 2001). In addition, resident CNS 
cells, such as microglia/macrophages and astrocytes in active MS le-
sions also express MMP9, mainly around the perivascular areas but 
also in the CNS parenchyma (Cuzner et al., 1996; Maeda & Sobel, 
1996). In mixed active/inactive lesions, MMP9 is more prominently 
localized at the edge of the lesions (Anthony et al., 1997), while 
this protease is occasionally also present in astrocytes in inactive 
lesions. These data further suggest that MMP9 is upregulated and 
exert its functions in active demyelinating lesions during inflamma-
tion. In addition to the stimulation of inflammatory cell infiltration 
through BBB disruptions, MMP9 derived from leukocytes cleaves 
MBP and may be involved in the degradation of myelin membranes 
(Gijbels et al., 1993; Proost, Van Damme, & Opdenakker, 1993). In 
contrast, MMP9 has also beneficial roles for remyelination (Larsen 
et al., 2003; Oh et al., 1999; Siskova et al., 2009; Uhm, Dooley, Oh, & 
Yong, 1998). Localization of MMP9 at the tips of the extending pro-
cesses of oligodendrocytes is essential for their outgrowth, that is 
process elongation and arborization is reduced in absence of MMP9 
(Oh et al., 1999; Uhm et al., 1998) and upon mislocalization of its 
activity (Siskova et al., 2009). In addition, MMP9 produced by mac-
rophages and microglia in the remyelination phase degrades NG2, a 
membrane-spanning CSPG present on OPCs that inhibits matura-
tion of oligodendrocytes (Larsen et al., 2003). Hence, MMP9 plays a 
dual role in MS. The activity of this enzyme in active demyelinating 
lesions may be detrimental and contribute to the pathogenesis and 
progression of MS, but beneficial functions of MMP9 are observed 
for remyelination, in which it facilitates oligodendrocyte maturation 
via ECM remodeling.
5.4 | MMP2
MMP2, is another member of the gelatinase family, also referred to 
as gelatinase A, and is in contrast to MMP3, MMP9, and MMP12, 
constitutively expressed in the CNS and CSF (Anthony et al., 1997; 
Rosenberg, 2002). MMP2 mRNA expression is not altered during de-
myelination and remyelination in a cuprizone-induced demyelination 
model (Skuljec et al., 2011), and only minor upregulation is observed 
in EAE (Weaver et al., 2005), in TME (Ulrich et al., 2006) and ac-
tive MS lesions (Lindberg et al., 2001; Mohan et al., 2010). However, 
MMP2 protein is present in macrophages and infiltrating cells in 
the perivascular area of active MS lesions (Anthony et al., 1997; 
Diaz-Sanchez et al., 2006; Maeda & Sobel, 1996). MMP2-expressing 
macrophages are also present at the border of mixed active/inactive 
lesions, while its expression in chronic lesions is only perivascular 
(Anthony et al., 1997; Diaz-Sanchez et al., 2006). As MMP9, MMP2 is 
likely involved in disruption of the BBB (Rosenberg et al., 1992) and 
has the highest activity in MBP degradation (Chandler et al., 1995; 
Diaz-Sanchez et al., 2006). MMP2 appears to be more abundant in 
MS lesions than MMP9, and its expression is predominant in areas 
of damaged axons, particular at lesion borders (Diaz-Sanchez et al., 
2006). Interestingly, MMP2 is also upregulated in NAWM areas ad-
jacent to the lesions (Anthony et al., 1997; Diaz-Sanchez et al., 2006; 
Maeda & Sobel, 1996). Also, higher levels of MMP2 are present in 
serum of MS patients (Bar-Or et al., 2003; Benesova et al., 2009). 
Whether MMP2 may play a role in regeneration of myelin other than 
its potential to locally degrade only CSPGs, but not laminin, which 
is present in the same area (Zuo, Ferguson, Hernandez, Stetler-
Stevenson, & Muir, 1998), remains to be determined.
5.5 | MMP7
MMP7, also called matrilysin, is constitutively expressed in the brain 
(Anthony et al., 1997; Wang et al., 2018). However, its mRNA levels 
are at the lower limit of detection (Clements et al., 1997; Mohan et al., 
2010). Given that MMP7 has a potent activity and a broad substrate 
specificity, it has been suggested that MMP7 may be a regulator of 
ECM turnover in the healthy brain (Anthony et al., 1997). MMP7 
mRNA expression is neither increased upon cuprizone-induced de-
myelination (Skuljec et al., 2011) nor in the TME (Ulrich et al., 2006) 
model, while MMP7 mRNA levels were increased upon lysolecithin-
induced demyelination, and early remyelination (Wang et al., 2018). 
In the latter model, MMP7 is localized extracellularly and present 
in microglia/macrophages (Wang et al., 2018). Contrasting findings 
are reported in EAE models. In a mouse MOG peptide-induced EAE 
model MMP7 mRNA levels remain similar (Weaver et al., 2005), 
while MMP7 mRNA is increased by 500-fold during the course and 
as protein present in invading macrophages in a MOG-induced rat 
EAE model (Clements et al., 1997) and increased at the peak of an 
adoptive-transfer rat EAE model (Kieseier et al., 1998). Also, con-
trasting findings have been reported for MMP7 mRNA levels in MS 
lesions: MMP7 mRNA expression is increased in all lesion types in 
some studies (Cossins et al., 1997; Lindberg et al., 2001), while it 
was undetectable in active and chronic MS lesions in another study 
(Mohan et al., 2010). MMP7 protein is localized to parenchymal mac-
rophages and occasionally observed in astrocytes in active MS le-
sions with a weaker expression in the center than at the edge of the 
lesion (Cossins et al., 1997; Wang et al., 2018). MMP7 expression in 
macrophages is also prominent at the lesion borders of mixed active/
inactive MS lesions (Anthony et al., 1997) and not as prominent in 
the center (Cossins et al., 1997), while biochemical analysis reveals 
that proMMP7 expression is reduced in mixed active/inactive and 
inactive lesions (Wang et al., 2018). In remyelinated lesions, total 
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expression levels of MMP7 are comparable to control white mat-
ter of healthy subjects with occasional expression in macrophages 
(Wang et al., 2018). MMP7 is not elevated in serum of MS patients, 
which is in contrast to MMP9 and MMP2 (Bar-Or et al., 2003). The 
exact role of MMP7 is not well understood, but like the other MMPs, 
a role in extravasation of monocytes into the tissue and migration 
of macrophages through remodeling of basement membrane ECM, 
such as proteoglycans, fibronectin, laminin, and elastin, can be fore-
seen. In addition, MMP7 potentially induces bystander demyelina-
tion and axonal loss, although likely to a lesser extent than MMP2 
and MMP9 (Anthony et al., 1997). However, when expressed in the 
CNS parenchyma in a timely manner, MMP7 may also be beneficial 
in clearing the transiently expressed ECM components and myelin 
debris (Chandler et al., 1995).
5.6 | Other MMPs
Other MMPs that have been analyzed at the protein level in MS le-
sions are MMP1 (Maeda & Sobel, 1996), MMP19 (van Horssen et al., 
2006), and MMP28 (Werner, Dotzlaf, & Smith, 2008). MMP1 is ex-
pressed in the majority of macrophages in active MS lesions (Maeda 
& Sobel, 1996). MMP19 is constitutively expressed by microglia in 
the healthy adult CNS, and highly expressed in macrophages in the 
parenchyma and perivascular areas in active MS lesions and in the 
rim of mixed active/inactive lesions, and occasionally by reactive as-
trocytes (van Horssen et al., 2006). Also, MMP19 mRNA levels are in-
creased in active and inactive MS lesions (Mohan et al., 2010). While 
the function of MMP19 in MS pathology remains to be established, 
it is interesting to note that MMP19 specifically degrades the large 
isoform of tenascin-C of which the expression is reduced in active 
MS lesions and mixed active/inactive lesions borders (Table 1 and 
Figure 1; Stracke et al., 2000). Upregulated MMP28 expression has 
been shown in one demyelinated, uncharacterized MS lesion, and in 
EAE (Werner et al., 2008). In addition, MMP28 mRNA is increased 
in inactive MS lesions (Mohan et al., 2010). Moreover, Western blot 
analysis also shows a marked upregulation in NAWM compared to 
control white matter (Werner et al., 2008). In the adult CNS, MMP28 
is mainly expressed in neurons and is a negative regulator of myelina-
tion (Werner et al., 2008) and macrophage recruitment (Manicone 
et al., 2009), justifying more research on this protein.
In addition to the marked altered expression patterns of MMP3 
and MMP12, several other MMPs, including MT-MMPs, show al-
tered mRNA expression patterns upon cuprizone-induced demye-
lination (Skuljec et al., 2011). Thus, MMP11 mRNA is upregulated at 
remyelination, while MMP14 mRNA is upregulated upon both de-
myelination and remyelination. MMP15 mRNA has been reported 
to be downregulated at conditions of demyelination, while MMP24 
mRNA is downregulated at demyelination but upregulated at remy-
elination (Skuljec et al., 2011). Mohan et al. (2010) performed an 
extensive qPCR analysis of 23 MMPs in control white matter, ac-
tive and inactive MS lesions. In addition to the discussed MMPs, the 
mRNA levels of MMP11 and MMP14 are more than 2-fold higher in 
active lesions than in control white matter and MMP11, MMP14, 
and MMP17 mRNAs are increased in inactive lesions. In contrast, 
the mRNA levels of two MMPs (MMP15 and MMP23) and one MMP 
(MMP23) were downregulated by at least 50% in active and inactive 
lesions, respectively (Mohan et al., 2010). The cellular localization of 
these MMPs and their significance for ECM remodeling, remyelin-
ation, and MS lesion pathology remains to be determined. Of note, 
the expression levels of most of these MMPs are also altered in TME 
and EAE models (Ulrich et al., 2006; Weaver et al., 2005).
6  | MMP DYSFUNC TION IN MS LESIONS
MMPs benefit remyelination by clearing the transiently expressed 
ECM proteins upon demyelination (Figure 4a). In MS lesions, ECM 
substrates are not appropriately degraded by MMPs, among others 
by the absence of MMPs in the lesion center and the inability of 
MMPs to process substrates at the lesion rim (Figure 4b). In addition, 
the interference of MMPs with basement membranes contributes to 
demyelination. In the following, we reflect on MMP dysfunction and 
how this may contribute to abnormal ECM expression in MS lesions.
6.1 | Altered MMP expression
The expression pattern of MMPs mainly reflects the inflammatory 
activity of the lesions. In fact, the distribution patterns of MMPs 
closely resemble each other, mainly localizing in macrophages, often 
in close association with vasculature, predominantly present in ac-
tive lesions. Concomitantly, and similar to the intralesional heteroge-
neity of ECM proteins, a more pronounced expression at the rim of 
mixed active/inactive MS lesion compared to the core of the lesion 
is usually observed. Furthermore, MMPs in MS lesions are only oc-
casionally present in astrocytes, with the exception of MMP3, which 
is primarily localized to astrocytes (Figure 4b). Likely, most MMPs 
in MS lesions are implicated in disruption of the BBB by affect-
ing its permeability upon enzymatic cleavage of ECM molecules in 
the basement membrane, such as type IV collagen, fibronectin and 
laminin, which enables the inflammatory cells, that is lymphocytes 
and monocytes to infiltrate the CNS (Leppert, Lindberg, Kappos, & 
Leib, 2001). Also, most MMPs present in inflammatory lesions de-
grade MBP, which may enhance demyelination and, in turn, contrib-
utes to axonal damage (Anthony et al., 1998). However, since MBP 
is an intracellular, peripheral protein, prior myelin degeneration 
is obviously required to allow proteolytic accessibility of the pro-
tein. In fact, the potential of MMPs to degrade MBP may indirectly 
facilitate clearance of remyelination-inhibiting myelin debris (Kotter 
et al., 2006).
Functional in vivo evidence for a role MMP-mediated remodel-
ing upon demyelination is currently lacking. Therefore, it is unclear 
whether the mainly microglia/macrophage-derived MMPs in MS 
are involved in the dynamic turnover of interstitial ECM upon de-
myelination. As remyelination fails, among others by the persistent 
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F I G U R E  4   Schematic representation of interstitial extracellular matrix (ECM) remodeling upon toxin-induced demyelination in 
experimental rodent models and in chronic demyelinated MS lesions. Upon demyelination, ECM remodeling, that is transient changes 
in the expression of ECM proteins and the proteolytic enzymes matrix metalloproteinases (MMPs), regulates oligodendrocyte behavior 
and thereby remyelination. (a) MMPs and their (ECM) targets in experimental toxin-induced demyelination rodent models of successful 
remyelination. MMPs are expressed by microglia/macrophages and astrocytes and benefit remyelination by (1) degrading the transiently 
expressed ECM proteins, (2) clearing myelin debris, and (3) by releasing insulin-like growth factor (IGF) from IGF-binding proteins. (b) MMPs 
and their (ECM) targets in chronic-demyelinated MS lesions. Note that MS lesions are characterized by intralesional heterogeneity in the 
expression of MMPs and ECM proteins, that is in the rim and center of the lesion. MMPs are mainly expressed by microglia/macrophages 
and contribute to demyelination by interfering with blood–brain barrier integrity. In addition, MMPs fail to degrade ECM proteins at the rim 
of MS lesions, and are absent at the lesion center, resulting in the accumulation of ECM proteins that inhibit oligodendrocyte progenitor 
cell differentiation. Of relevance, functional in vivo evidence for a role of most MMPs in ECM remodeling is currently lacking. Therefore, 
the indication of their ability to clear (green scissors) or not to clear (red scissors) their targets is based on their presence, their ability to 
degrade the indicated substrate, and the transient (cleared) or persistent (not cleared) presence of the indicated substrate. Note the distinct 
cellular expression of MMPs and ECM proteins in experimental rodent models and MS lesions. Thrombospondin-1 expression is increased 
in chronic demyelinated MS lesions, while data on (cellular) localization are not available. A-can, aggrecan; Fn, fibronectin; HA, hyalorunan; 
N-can, neurocan; OPN, osteopontin; P-can, phosphocan; Tn-C, tenascin-C; Tn-R, tenascin-R; TSP, thrombospondin-1; V-can, versican; Vn, 
vitronectin
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presence of interstitial ECM components (Table 1, Figures 1 and 
2), a dysfunction in MMP expression and/or their activation are 
more likely relevant parameters in this regard. As discussed above, 
the composition of both ECM molecules and ECM-degrading 
MMPs differ between demyelinating injury in experimental rodent 
models and the distinct white matter MS lesions (summarized in 
Tables 1 and 2). The tightly and temporal (cellular) expression of sev-
eral MMPs regulate the clearance of the transiently expressed ECM 
molecules to enable regeneration of myelin (Figure 4a). In contrast, 
in MS lesions, where remyelination fails, a different and more per-
sistent pattern of MMPs and ECM molecules is observed (Figure 4b; 
Agrawal et al., 2008; van Horssen et al., 2007). For example, the 
mRNA levels of gelatinases MMP2 and MMP9 are not (MMP2) or 
transiently (MMP9) upregulated upon demyelination and remyelin-
ation models (Larsen et al., 2003; Skuljec et al., 2011), but these 
enzymes are highly expressed in active and mixed active/inactive 
MS lesions (Anthony et al., 1997; Cossins et al., 1997; Cuzner et al., 
1996; Lindberg et al., 2001; Maeda & Sobel, 1996). The disturbed 
ECM in MS lesions may regulate the expression of these MMPs. 
Fibronectin increases the expression levels and proteolytic activ-
ity of MMP2 and MMP9 by T-lymphocyte cell lines (Esparza et al., 
1999). Also, fibronectin and vitronectin induce the expression of 
MMP9 in microglia (Milner et al., 2007), and trombospondin-1 reg-
ulates MMP2 and MMP9 activity (Bein & Simons, 2000; Rodriguez-
Manzaneque et al., 2001; Taraboletti et al., 2000) and influences 
the balance between MMPs and inhibitors (TIMP) in tumor cells 
(John, Hu, Rothman, & Tuszynski, 2009). Moreover, gelatinases, and 
MMP9 in particular, are not the most efficient proteases in prote-
olysis of ECM proteins (Fosang et al., 1992; Imai, Shikata, & Okada, 
1995; Muir et al., 2002; Murphy, Cockett, Ward, & Docherty, 1991; 
Siri et al., 1995). Rather, spatial temporal regulation of MMP2 and 
MMP9 expression may be more important. Thus, MMP9 cleaves 
membrane-spanning CSPG NG2, allowing (morphological) oligo-
dendrocyte differentiation (Larsen et al., 2003), while incorrect 
localization of MMP9, as mediated by fibronectin, perturbs oligo-
dendrocyte process branching (Siskova et al., 2009). Also, MMP2, 
present at the tips of the axonal extensions, eliminates the CSPG-
mediated inhibition of laminin through specific proteolytic cleavage 
of CSPGs rather than laminin, which is beneficial to regeneration 
(Zuo et al., 1998). However, MMP2 and MMP9 are also potent in-
ducers of BBB disruption and axonal injury (Anthony et al., 1997; 
Diaz-Sanchez et al., 2006), and may induce bystander demyelin-
ation via degradation of MBP (Chandler et al., 1995). Hence, MMP2 
and MMP9 may contribute more to a demyelinating MS pathology 
than to interstitial ECM remodeling for remyelination.
6.2 | MMPs are present at the rim of chronic 
MS lesions
MMP7 and MMP3 are more potent proteases to degrade the inter-
stitial ECM, present in MS lesions (Imai et al., 1995; Muir et al., 2002; 
Murphy et al., 1991; Siri et al., 1995). Therefore, these MMPs are 
potentially able to reintroduce a permissive environment for remyeli-
nation and improve the neuropathological conditions in MS. Indeed, 
both MMPs are upregulated at remyelination following demyelina-
tion in experimental rodent models (Skuljec et al., 2011; Wang et al., 
2018). MMP3 degrades the CSPGs, aggrecan, versican, neurocan, 
and phosphacan, while MMP7 cleaves aggrecan (Fosang et al., 1992; 
Muir et al., 2002). However, while CSPG expression is reduced in the 
center of active MS lesions, where MMP3-expressing astrocytes and 
MMP7-expressing macrophages are located, there is still accumula-
tion of CSPGs at the lesions borders, where MMP7 expression is 
more prominent. Therefore, it may be hypothesized that MMP3 and 
MMP7 are actively degrading CSPGs in the center of active lesions, 
while these MMPs are not active at the lesion edges. Indeed, immu-
nohistochemistry identifies and spatially localizes MMP, but it does 
not distinguish active from inactive MMP. Moreover, in MS lesions, 
most of the MMPs reside within cells and often no extracellular 
staining is noticed, while for interstitial ECM remodeling MMPs have 
to be secreted and activated. Activation of MMPs by other proteases 
is spatially focused and regulated by other MMPs or plasmin, which 
is locally generated by tissue-type plasminogen activator (t-PA; Lu 
et al., 2011; Page-McCaw et al., 2007). While absent in control white 
matter, in MS lesions t-PA is expressed in macrophages and its ex-
pression pattern is comparable to MMP expression, that is present 
in active and absent in chronic lesions (Cuzner et al., 1996). Another 
tightly regulated mechanism for MMP actions is the regulation of its 
activity by TIMPs (Lu et al., 2011; Page-McCaw et al., 2007). Upon 
toxin-induced demyelination, increased mRNA levels of TIMP1 and 
TIMP2 are observed at demyelination, followed by a gradual decline 
during remyelination (Skuljec et al., 2011; Wang et al., 2018). TIMP3 
is transiently upregulated in the first week during demyelination, 
whereas TIMP4 is upregulated during remyelination (Skuljec et al., 
2011). Lindberg et al. (2001) show that the mRNA levels of these 
TIMPS are not significantly altered at all MS lesion types. In con-
trast, Mohan et al. (2010) show that both TIMP1 and TIMP3 mRNA 
are upregulated in active and inactive lesions, while TIMP3 mRNA 
are downregulated in inactive lesions. Immunohistochemistry of 
TIMPs may reveal the expression patterns and cellular localization 
of TIMPs, and whether the delicate balance between MMP and their 
inhibitors is disturbed in MS lesions, that is interfere with interstitial 
ECM remodeling. Also, an in situ MMP activity assay on MS lesions 
may provide insight in localized MMP activity levels. Of note, inhib-
iting MMP activity reduced the clinical symptoms in an EAE model 
by reducing the breakdown of the BBB and demyelinating pathol-
ogy (Gijbels, Galardy, & Steinman, 1994; Liedtke et al., 1998). Hence, 
although modulation of MMP activity can be an advantageous ap-
proach, it remains to be determined whether MMP activity within 
the CNS is actually inhibited in this model.
In contrast to CSPGs, tenascin expression is reduced in active le-
sions and the lesion border of inactive lesions, indicating proteolytic 
activity at these sites. Upon alternative splicing, a large and small 
isoform of tenascin-C are generated. The small variant is more re-
sistant to degradation, but cleaved by MMP7, while MMP3, MMP7, 
MMP12, and MMP19 degrade large tenascin-C. Also, other, yet 
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undefined MMPs, or even non-related proteases, such as cathepsin 
B (Bever & Garver, 1995; Mai, Sameni, Mikkelsen, & Sloane, 2002), 
may clear tenascins in active MS lesions and at the border of mixed 
active/inactive lesions.
6.3 | MMPs are absent in the center of chronic 
MS lesion
MMPs are hardly present in inactive and in the center of mixed ac-
tive/inactive lesions, which may be the main reason why the ECM 
proteins, fibronectin and osteopontin, persist. While loss of func-
tion studies demonstrated that fibronectin (Stoffels et al., 2015) and 
osteopontin (Zhao et al., 2008) are redundant for remyelination, 
the persistence of otherwise transient ECM proteins in MS lesions, 
such as fibronectin (aggregates), results in a gain of function, that is 
they perturb OPC differentiation. Why MMPs are not upregulated 
in chronic MS lesions is not known. It may be hypothesized that the 
cellular source of MMPs might determine whether these enzymes 
perform beneficial or detrimental roles in MS lesions. This is sup-
ported by observations that MMP12 is initially produced by micro-
glia/macrophages, while the protease localizes to astrocytes and 
oligodendrocytes, as observed at successful remyelination, which 
is beneficial for remyelination. Also, the CSPG-enriched barrier at 
the lesion border may prevent the migration of cells that produce 
a suitable MMP to the lesion center. CSPGs are reduced in the le-
sion center, indicating that they are cleared, but not resynthesized 
to reestablish the interstitial ECM in adult healthy CNS. Indeed, 
mRNA levels of CSPGs are reduced in inactive MS lesions (Mohan 
et al., 2010), which may be due to the lack of sufficient and/or the 
presence of misactivated microglia/macrophages, the main pro-
ducers of CSPGs, in the center of lysolecithin-induced lesions (Lau 
et al., 2012). In this regard, it will be of interest to analyze the ECM 
composition of remyelinated lesions. In remyelinated lesions, MMP7 
levels are comparable to control white matter (Wang et al., 2018), 
while fibronectin levels are still increased (Stoffels et al., 2013). 
Of note, astrocyte-derived HMW hyaluronan, which is highly ex-
pressed in chronic MS lesions, is degraded by the hyaluronidase 
family rather than by MMPs (Wang et al., 2018; Wang, Wang, & Li, 
2017). Similarly, thrombospondin-1 is also not cleaved by MMPs 
(Iruela-Arispe, 2008).
7  | CONCLUDING REMARKS AND 
PERSPEC TIVES
Upon demyelinating injury, remodeling of the interstitial ECM is 
essential in guiding oligodendrocyte behavior to succeed success-
ful remyelination. Remodeling of the interstitial ECM upon demy-
elination in MS lesions, including the expression patterns of ECM 
molecules and MMPs, is dependent on the nature of and the lo-
calization within lesions, and differs from ECM remodeling upon 
demyelinating injury in experimental rodent models that show 
successful recovery (Figure 4). More specifically, the transient 
upregulation of ECM proteins, as a natural response to demyeli-
nation, persists in MS lesions, among others by dysregulation of 
MMP expression, their localization and, likely, their activation. 
Several MMPs are upregulated in a seemingly uncontrollable man-
ner (MMP2 and MMP9), while others (MMP3, MMP7, and MMP12) 
that perform beneficial functions for remyelination upon demyeli-
nation in CNS white matter in rodent models are absent or incor-
rectly located in MS lesions. Also, and in contrast to demyelination 
in experimental models, MMPs are mainly expressed by microglia/
macrophages and hardly, with the exception of MMP3, by astro-
cytes (Figure 4). In addition, the phenotype of astrocytes, produc-
ers of ECM molecules in the CNS, is changed as a consequence of 
the ensuing spatially focused inflammation, leading to the forma-
tion of at least two glial scars: one at the border of active and 
inactive lesions, which is enriched in CSPGs, and the other within 
the center of MS lesions that is devoid of CSPGs, but enriched in 
fibronectin aggregates, osteopontin, and hyaluronan.
Taking the effect on OPC behavior into account, the persistent 
presence of mainly OPC differentiation-inhibiting ECM proteins and 
the absence of myelination-promoting laminin in MS lesions contrib-
ute to remyelination failure. As a therapeutic strategy, it is essential 
to clear or bypass these dominant OPC differentiation-inhibiting 
ECM proteins, as targeted upregulation of remyelination-promot-
ing laminin may not be efficient to enable regeneration of myelin. 
Therefore, the ECM environment in MS lesions should also be taken 
into account when determining the effectiveness of potential remy-
elination-inducing compounds that are based on stimulating endog-
enous OPCs or when a cell therapy with exogenous remyelinating 
cells is considered as a strategy to promote remyelination in MS 
lesions.
Local activation of MMPs, that is in the rim and/or lesions cen-
ter with an appropriate substrate specificity, may be a means to 
degrade ECM depositions and reinstate a permissive environment 
for remyelination, as is the case in recovery upon demyelination 
in experimental models. However, the dual role of MMPs, such as 
their ability to degrade vascular basement membrane ECM com-
ponents and to induce axonal injury and myelin loss, complicates 
the development of treatment strategies, aimed at correct inter-
stitial ECM remodeling in favor of remyelination. Thus, MMPs con-
tribute to damage at early lesions stages, while their absence at 
later stages is detrimental to interstitial ECM remodeling, which, 
in turn, is essential for the regeneration of myelin. In fact, as mi-
croglia/macrophages have also receptors for ECM proteins, the 
dysregulated interstitial ECM in MS lesions also affects microg-
lia/macrophage activation (Austin et al., 2012; Ebert et al., 2008; 
Milner et al., 2007; Rolls et al., 2008; Sikkema et al., 2018), which 
may not only affect MMP expression, but also indirectly contrib-
ute to OPC differentiation and therefore remyelination (Lloyd & 
Miron, 2019; Miron et al., 2013). Hence, means to overcome the 
dysregulated activation of microglia/macrophages in white matter 
MS lesions (Peferoen et al., 2015; Vogel et al., 2013) may indirectly 
also reinstall correct ECM remodeling.
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